<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="334994">
  <stage>Registered</stage>
  <submitdate>7/01/2010</submitdate>
  <approvaldate>13/01/2010</approvaldate>
  <actrnumber>ACTRN12610000038099</actrnumber>
  <trial_identification>
    <studytitle>Measuring heart muscle oxygenation in chest pain syndromes</studytitle>
    <scientifictitle>Measuring Impairments in Myocardial Oxygenation in Chest Pain Syndrome Patients using Blood-level Dependent Magnetic Resonance Imaging</scientifictitle>
    <utrn>U1111-1113-1938</utrn>
    <trialacronym>BOLD-MRI</trialacronym>
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Left ventricular hypertrophy</healthcondition>
    <healthcondition>Hibernating myocardium</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Stress imaging with cardiac magnetic resonance (CMR)with half of the subjects receiving adenosine intravenously(140mcg/kg/min) for 3-6 mins once only during the CMR and the other half receiving dobutamine intravenously (maximal dose-40mcg/kg/min) once only during CMR, all subjects have an echocardiograph once only either before or after the CMR, for those subjects in the hibernating part of the study , (those patients who will have a revascularisation either coronary artery bypass graftingor percutaneous coronary intervention) only adenosine (140mcg/kg/min) for 3-6 mins will be used during the CMR. These subjects will have two CMR's one at baseline and then one six months post revascularisation.</interventions>
    <comparator>20 age-sex matched volunteers will have stress imaging with 10 receiving intravenous adenosine and 10 receiving intravenous dobutamine, along with the cardiac magnetic resonance imaging and echocardiography. All 20 volunteers will be in the control group.</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Patients with left ventricular hypertrophy presenting with chest pain and/or exertional breathlessness with normal epicardial arteries have direct impairments in myocardial tissue oxygenation. Perfusion reserve and blood-level dependent (BOLD) signal will be determined in the treatment group versus the control group. Assessed by cardiac magnetic resonance imaging and echocardiography.</outcome>
      <timepoint>Baseline</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Hibernating myocardial segments will maintain myocardial oxygenation levels similar to remote normal myocardium both in rest and stress. Regional wall motion, perfusion and oxygenation will be assessed by cardiac magnetic resonance imaging and echocardiography in the hibernating group versus the control group</outcome>
      <timepoint>Baseline and 6 months post revascularisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>none</outcome>
      <timepoint>none</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. History of hypertension, left ventricular hypertrophy, exertional chest pain and/or breathlessness, normal epicardial arteries
2. Known coronary artery disease, impaired regional left ventricular function awaiting percutaneous coronary intervention or coronary artery bypass grafting</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Inability to give written informed consent, estimated Glomerular Filtration Rate(GFR)&lt;60mls/min, extreme claustrophobia, implantable cardiac devices and other contra-indications to Magnetic Resonance Imaging(MRI) (i.e. metal in eyes), asthma or other reversible bronchospasm</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/02/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>65</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Southern Adelaide Health Service</primarysponsorname>
    <primarysponsoraddress>Laffer Drive
Science Park
BEDFORD PARK SA 5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Heart Foundation Grant-In-Aid</fundingname>
      <fundingaddress>National Heart Foundation
Level 2 500 Collins Street
Melbourne. Victoria 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
Flinders Drive
BEDFORD PARK SA 5042</ethicaddress>
      <ethicapprovaldate>20/02/2009</ethicapprovaldate>
      <hrec>31/09</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Joseph Selvanayagam</name>
      <address>Department of Cardiovascular Medicine
Flinders Medical Centre
1 Flinders Drive,
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8404 2195</phone>
      <fax />
      <email>joseph.selvanayagam@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Christine Edwards</name>
      <address>Department of Cardiovascular Medicine
Flinders Medical Centre
1 Flinders Drive,
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8204 5765</phone>
      <fax>+61 8 8204 7047</fax>
      <email>christine.edwards2@health sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Christine Edwards</name>
      <address>Department of Cardiovascular Medicine
Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK SA 5042</address>
      <phone>+61 8 8204 5765</phone>
      <fax>+61 8 8204 7047</fax>
      <email>christine.edwards2@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>